Fluifort, 5 g 10 pcs

Fluifort has mucoregulatory, expectorant action.

Pharmacodynamics

The mucolytic and expectorant action is due to the activation of sialic transferase – an enzyme of the mucous membrane of the bronchi. It normalizes the quantitative ratio of acidic and neutral sialomucin of bronchial secretion, restores viscosity and elasticity of mucus.

Promotes regeneration of the mucous membrane, normalizes its structure, activates the ciliated epithelium. Restores the secretion of immunologically active IgA (specific protection) and the number of sulfhydryl groups of mucus components (nonspecific protection), improves mucociliary clearance.

Pharmacokinetics

It is rapidly and completely absorbed after oral administration. C_max in blood and secretion is reached within the first hour after drug administration. Therapeutic concentration is retained in the blood for 8 hours. T_1/2 is 1.8 hours (at a dose of 2 g/day).

Extracted mainly in the urine, about 30-60% is unchanged, the rest as metabolites.

Indications

Acute and chronic bronchopulmonary diseases accompanied by the formation of viscous sputum

Pharmacological effect

Fluifort has a mucoregulatory and expectorant effect.

Pharmacodynamics

The mucolytic and expectorant effect is due to the activation of sialic transferase, an enzyme of goblet cells of the bronchial mucosa. Normalizes the quantitative ratio of acidic and neutral sialomucins in bronchial secretions, restores the viscosity and elasticity of mucus.

Promotes the regeneration of the mucous membrane, normalizes its structure, and activates the activity of the ciliated epithelium. Restores the secretion of immunologically active IgA (specific protection) and the amount of sulfhydryl groups of mucus components (nonspecific protection), improves mucociliary clearance.

Pharmacokinetics

Rapidly and completely absorbed after oral administration. Cmax in blood and secretions is achieved within the first hour after taking the drug. The therapeutic concentration remains in the blood for 8 hours. T1/2 is 1.8 hours (at a dosage of 2 g/day).

It is excreted mainly in the urine, approximately 30–60% unchanged, the rest in the form of metabolites.

Special instructions

From the first days of taking the drug, due to improved secretion removal, the expectorant effect increases.

Fluifort in the form of granules for preparing a suspension contains a sweetener – aspartame. This substance is contraindicated in patients suffering from phenylketonuria.

Active ingredient

Carbocysteine

Composition

1 sachet of granules for oral suspension contains:

active ingredient:

carbocisteine ​​lysine salt monohydrate 2.7 g,

excipients:

citric acid – 0.080 g;

mannitol – 0.9185 g;

PVP – 0.1 g;

natural cedar flavoring – 0.04 g;

natural orange flavoring – 0.04 g;

orange juice powder – 0.2960 g;

aspartame – 0.03 g;

maltosodextrin – 0.7955 g

Pregnancy

Not recommended in the first trimester of pregnancy; breastfeeding should be stopped during treatment.

Contraindications

hypersensitivity to carbocisteine;
peptic ulcer of the duodenum and stomach (in the acute phase);
children under 1 year of age (for syrup) or 16 years of age (for granules for preparing a suspension);
pregnancy (first trimester);
lactation period;
phenylketonuria (for granules for suspension preparation).

With caution: pregnancy (II–III trimester); peptic ulcer of the stomach and duodenum (history).

Side Effects

The following side effects are typical for carbocisteine: rarely – gastritis, nausea, diarrhea, dizziness, malaise, skin rash.

Lysine salt of carbocysteine: rarely – epigastric pain, nausea, diarrhea; skin rash.

All of these disorders are transient in nature and disappear after stopping the drug or after reducing the dosage.

If any side effect develops, you should consult your doctor.

Interaction

Currently, there are no known cases of interaction between carbocisteine ​​and drugs commonly used in the treatment of respiratory diseases.

There was no interaction between the drug and food, as well as substances used for laboratory research.

The effect is weakened by antitussive and anticholinergic drugs.

Increases the effectiveness of GCS (mutually) and antibacterial therapy for infectious and inflammatory diseases of the upper and lower respiratory tract.

Enhances the bronchodilator effect of theophylline.

Overdose

Currently, no cases of overdose with Fluifort have been reported.

Symptoms: possible stomach pain, nausea, diarrhea.

Treatment: symptomatic. There is no specific antidote.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Dompe Pharmaceutici S.p.A., Italy